Home › Compare › ORPHY vs MO

ORPHY vs MO: Dividend Comparison 2026

ORPHY yields 6666.67% · MO yields 9.11%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ORPHY wins by $1028095347812062.00M in total portfolio value
10 years
ORPHY
ORPHY
● Live price
6666.67%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1028095347812062.00M
Annual income
$998,628,545,336,266,700,000.00
Full ORPHY calculator →
MO
Altria Group Inc.
● Live price
9.11%
Share price
$44.80
Annual div
$4.08
5Y div CAGR
4.3%
Payout ratio
78%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.7K
Annual income
$4,052.72
Full MO calculator →

Portfolio growth — ORPHY vs MO

📍 ORPHY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodORPHYMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ORPHY + MO cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
ORPHY pays
MO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ORPHY
Annual income on $10K today (after 15% tax)
$566,666.67/yr
After 10yr DRIP, annual income (after tax)
$848,834,263,535,826,600,000.00/yr
MO
Annual income on $10K today (after 15% tax)
$774.11/yr
After 10yr DRIP, annual income (after tax)
$3,444.81/yr
At 15% tax rate, ORPHY beats the other by $848,834,263,535,826,600,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ORPHY + MO for your $10,000?

ORPHY: 50%MO: 50%
100% MO50/50100% ORPHY
Portfolio after 10yr
$514047673906031.00M
Annual income
$499,314,272,668,133,360,000.00/yr
Blended yield
97.13%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

ORPHY
No analyst data
MO
Analyst Ratings
16
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$61.25
+36.7% upside vs current
Range: $47.00 — $68.00
Altman Z
3.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ORPHY buys
0
MO buys
0
No recent congressional trades found for ORPHY or MO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricORPHYMO
Forward yield6666.67% ✓9.11%
Annual dividend / share$2.00$4.08 ✓
Payout ratio50% ✓78%
1-year div growth0%4.1% ✓
5-year div CAGR0%4.3% ✓
Portfolio after 10y$1028095347812062.00M ✓$27.7K
Annual income after 10y$998,628,545,336,266,700,000.00 ✓$4,052.72
Total dividends collected$1026118102492338.88M ✓$20.9K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: ORPHY vs MO ($10,000, DRIP)

YearORPHY PortfolioORPHY Income/yrMO PortfolioMO Income/yrGap
1← crossover$677,367$666,666.67$10,740$949.88+$666.6K → ORPHY
2$42,928,313$42,203,530.63$11,601$1,086.84+$42.92M → ORPHY
3$2,545,616,701$2,499,683,405.64$12,608$1,250.75+$2545.60M → ORPHY
4$141,255,910,403$138,532,100,533.89$13,792$1,448.20+$141255.90M → ORPHY
5$7,335,374,338,812$7,184,230,514,680.15$15,190$1,687.69+$7335374.32M → ORPHY
6$356,516,885,536,661$348,668,034,994,132.70$16,851$1,980.28+$356516885.52M → ORPHY
7$16,218,956,689,966,618$15,837,483,622,442,392.00$18,838$2,340.48+$16218956689.95M → ORPHY
8$690,711,023,145,868,900$673,356,739,487,604,600.00$21,230$2,787.44+$690711023145.85M → ORPHY
9$27,539,067,734,387,980,000$26,800,006,939,621,900,000.00$24,130$3,346.72+$27539067734387.95M → ORPHY
10$1,028,095,347,812,062,000,000$998,628,545,336,266,700,000.00$27,676$4,052.72+$1028095347812062.00M → ORPHY

ORPHY vs MO: Complete Analysis 2026

ORPHY — Stock

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative rare diseases. The company offers heat stock proteins that focuses on the treatment of neurodegenerative diseases by harnessing the cell protective properties of the heat shock response, which protects cells from the accumulation of misfolded proteins, aggregated proteins, and dysfunctional lysosomes. Its lead candidate is the Arimoclomol, which is in clinical development for diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, and Inclusion Body Myositis. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.

Full ORPHY Calculator →

MO — Consumer Staples

Altria is a Dividend King with 54+ consecutive years of dividend increases — one of the longest streaks in American corporate history. While cigarette volumes decline, pricing power and new product categories (oral nicotine pouches via NJOY) support cash flows. The near-9% yield is among the highest in the S&P 500.

Full MO Calculator →
📬

Get this ORPHY vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ORPHY vs SCHDORPHY vs JEPIORPHY vs OORPHY vs KOORPHY vs MAINORPHY vs PMORPHY vs BTIORPHY vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.